Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?
Breast Cancer Research and Treatment · 2026
DOI: 10.1007/s10549-026-08051-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Samuel Margolis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Breast Neoplasms, Drug Approval, Antineoplastic Agents. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH, Breast Cancer Research Foundation.
Abstract (Originalsprache)
Purpose
Patient-reported outcomes (PROs) inform benefit-risk tradeoffs in breast cancer treatment, yet reporting quality across registration trials remains incompletely characterized.
Methods
We conducted a scoping review of PRO reporting in randomized trials supporting FDA breast cancer drug approvals (January 2011–December 2024), identified via the FDA Oncology Approval Notifications database. Associated manuscripts were retrieved through systematic PubMed and EBSCO searches using trial-specific NCT identifiers. We assessed PRO endpoint prespecification status, instruments used, PRO publication delay (defined as the interval in months between the primary trial manuscript and corresponding PRO-dedicated manuscript publication date), and missing data reporting across eligible primary trial, PRO-dedicated, and subpopulation-specific PRO manuscripts.
Results
We identified 34 FDA breast cancer drug approvals supported by 36 unique randomized trials, yielding 45 eligible manuscripts. No trial designated PROs as a primary or co-primary endpoint; nine (25%) did not explicitly prespecify them. Median PRO publication delay was 18 months, with eight trials experiencing a delay of two or more years. Missing data handling methods were described in 33% of manuscripts and reasons for missingness in 11%.
Conclusion
In this scoping review, PROs were commonly collected but inconsistently prespecified, often delayed, and incompletely reported. Registration trials should strengthen PRO prespecification, reduce publication delay, and adhere to missing data reporting standards. Clinical trial number Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California, Los Angeles, CA, USA.
- Department of Medicine, University of California, Los Angeles, CA, USA. msedrak@mednet.ucla.edu.
- David Geffen School of Medicine at UCLA, 650 Charles Young Drive South, Room A2-125 CHS, Los Angeles, CA, 90095-6900, USA. msedrak@mednet.ucla.edu.
ORCID-Profile: Mina S Sedrak
Förderung
- NIA NIH HHS
- NIH
- Breast Cancer Research Foundation
Zitieren
APA
Margolis, S., Guirguis, A. N., Lee, C., Smith, S., LeVee, A., Lipsyc-Sharf, M. D., Bardia, A., & Sedrak, M. S. (2026). Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08051-y
Vancouver
Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, et al. Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08051-y
BibTeX
@article{Margolis2026,
author = {Margolis, Samuel and Guirguis, Andre Naguib and Lee, Catherine and Smith, Saiya and LeVee, Alexis and Lipsyc-Sharf, Marla D and Bardia, Aditya and Sedrak, Mina S},
title = {Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-026-08051-y}
}
EUVIMED